[{"address1": "2450 Holcombe Boulevard", "address2": "Suite X", "city": "Houston", "state": "TX", "zip": "77021", "country": "United States", "phone": "832 834 9144", "website": "https://www.salariuspharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.", "fullTimeEmployees": 2, "companyOfficers": [{"maxAge": 1, "name": "Mr. David J. Arthur M.B.A.", "age": 60, "title": "CEO, President & Director", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 513200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark J. Rosenblum CPA", "age": 70, "title": "Executive VP of Finance & CFO", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 343200, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.62, "open": 2.72, "dayLow": 2.67, "dayHigh": 3.2795, "regularMarketPreviousClose": 2.62, "regularMarketOpen": 2.72, "regularMarketDayLow": 2.67, "regularMarketDayHigh": 3.2795, "beta": 0.932, "forwardPE": -0.29334787, "volume": 577765, "regularMarketVolume": 577765, "averageVolume": 2145091, "averageVolume10days": 12519450, "averageDailyVolume10Day": 12519450, "bid": 2.34, "ask": 3.44, "bidSize": 100, "askSize": 100, "marketCap": 3876720, "fiftyTwoWeekLow": 1.22, "fiftyTwoWeekHigh": 7.2, "fiftyDayAverage": 1.6129, "twoHundredDayAverage": 2.368355, "currency": "USD", "enterpriseValue": -1255203, "floatShares": 1404883, "sharesOutstanding": 1441160, "sharesShort": 65040, "sharesShortPriorMonth": 15020, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.045100003, "heldPercentInsiders": 0.02517, "heldPercentInstitutions": 0.00364, "shortRatio": 0.08, "shortPercentOfFloat": 0.045500003, "impliedSharesOutstanding": 1441160, "bookValue": 10.74, "priceToBook": 0.25046557, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -6464335, "trailingEps": -5.14, "forwardEps": -9.17, "lastSplitFactor": "1:8", "lastSplitDate": 1718582400, "enterpriseToEbitda": 0.186, "52WeekChange": -0.39908254, "SandP52WeekChange": 0.22408533, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SLRX", "underlyingSymbol": "SLRX", "shortName": "Salarius Pharmaceuticals, Inc.", "longName": "Salarius Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1422541800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "f7c5d494-3e4a-33bc-9704-e2b0ec3dd19f", "messageBoardId": "finmb_330031056", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.69, "recommendationKey": "none", "totalCash": 3272823, "totalCashPerShare": 2.271, "ebitda": -6733092, "quickRatio": 2.777, "currentRatio": 2.982, "returnOnAssets": -0.53991, "returnOnEquity": -1.1983, "freeCashflow": -6133413, "operatingCashflow": -7686402, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-18"}]